Press Releases
Stay updated on the latest Vistagen News and get the details about important events, public financial reports, and our product pipeline updates.
Mar 11, 2013
Poster Will Discuss Expanded and Improved Applications of Novel Pluripotent Stem-Based Screening System for Heart Toxicity SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 03/11/13 -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue,
VistaGen Therapeutics Enters Strategic Collaboration With Celsis to Further Advance LiverSafe 3D(TM)
Mar 04, 2013
Companies Structure Collaboration to Focus on Development and Characterization of VistaGen's Human Pluripotent Stem-Cell Derived Liver Cells SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 03/04/13 -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for
Feb 07, 2013
Latest Developments Enable Advanced Tools for Drug Rescue and Potential Cell Therapies Based on Human Definitive Hematopoietic Precursor Cells SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 02/07/13 -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for
Lead Prodrug Candidate Is Being Developed for Chronic Neuropathic Pain SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 01/23/13 -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism screening, today
Jan 22, 2013
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 01/22/13 -- VistaGen Therapeutics, Inc. (OTCBB: VSTA) (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism screening, today announced that Shawn K.
Dec 03, 2012
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 12/03/12 -- VistaGen Therapeutics, Inc. (OTCBB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism screening, has formalized its membership in the Toronto-based Centre for
Nov 13, 2012
Novel Human Stem Cell-Based Bioassay Based on VistaGen's Human Clinical Trials in a Test Tube(TM) Platform SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 11/13/12 -- VistaGen Therapeutics, Inc. (OTCBB: VSTA) (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue,
Sep 06, 2012
Company Also Completes Long-Term Debt Restructuring SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 09/06/12 -- VistaGen Therapeutics, Inc. (OTCBB: VSTA) (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue and novel pharmaceutical assays for predictive heart and liver
May 14, 2012
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 05/14/12 -- VistaGen Therapeutics, Inc. (OTCBB: VSTA) (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, today issued the following letter to its stockholders and the investment community from its CEO, Shawn Singh.
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 04/25/12 -- VistaGen Therapeutics, Inc. (OTCBB: VSTA) (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, has secured a new United States patent covering the company's proprietary methods used to measure and type the toxic
